Scientific work

Prof. Dr. Mehmet Ali Vardar

158 publications. The source of the information is stated next to each publication.

Back to profile

  1. Feasibility and Concordance of a Large Language Model (ChatGPT-5) as a Clinical Decision Support Tool in Gynecologic Oncology Tumor Boards: A Blinded, Multi-Observer Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15124451 PMID 42355621 Source: OpenAlex

  2. Prognostic Significance of Immune Checkpoint Markers in Prognosis of Grade 3 Endometrioid Carcinoma

    Medicina, 2026

    DOI 10.3390/medicina62020327 PMID 41752726 Open-access full textSource: OpenAlex

  3. Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes

    International Journal of Gynecological Cancer, 2026

    DOI 10.1016/j.ijgc.2026.104693 PMID 42167105 Source: OpenAlex

  4. Feasibility and concordance of a large language model (ChatGPT-5) as a clinical decision support tool in gynecologic oncology tumor boards: A blinded, multi-observer study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.5519 Source: OpenAlex

  5. Prognostic Implications of Combined p53 and Mismatch-Repair Immunophenotypes in Uterine Carcinosarcoma

    Medicina, 2026

    DOI 10.3390/medicina62061135 PMID 42356147 Source: OpenAlex

  6. Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.11.020 PMID 41380962 6 citations (Europe PMC) Source: OpenAlex

  7. Peritonectomy procedures for peritoneal surface malignancies: PSOGI-ESGO-ISSPP Lyon consensus

    British journal of surgery, 2025

    DOI 10.1093/bjs/znaf112 PMID 40560098 12 citations (Europe PMC) Source: OpenAlex

  8. LBA44 Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.09.056 Source: OpenAlex

  9. Molecular Classification Of Serous And Clear Cell Endometrial Adenocarcinoma

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2024.100672 Source: OpenAlex

  10. Molecular Classification And Clinical Significance In Grade 3 Endometrial Adenocarcinoma

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2024.100671 Source: OpenAlex

  11. Minimally Invasive Approach To An Extraordinary Cervical Cancer Case With Gastrointestinal Stromal Tumor And Low Grade Appendiceal Neoplasia Mimicking Metastatic Disease

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2024.100546 Source: OpenAlex

  12. Live Surgical Retroperitoneal Anatomy Of The Right Upper Quadrant And Suprarenal-Retrocaval Bulky Lymph Node Excision

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2024.100174 Source: OpenAlex

  13. Excision Of A Conglomerated Bulky Lymph Nodes From Left Lumbo-Sacroileal Area And Obturator Fossa With Anatomic Demonstration Of Major Neural And Vascular Anatomic

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2024.100159 Source: OpenAlex

  14. Prognostic significance of prognostic nutritional index in high-grade serous ovarian cancer: a comparative analysis with other prognostic factors

    Çukurova medical journal (Online)/Çukurova medical journal, 2025

    DOI 10.17826/cumj.1639156 Source: OpenAlex

  15. Molecular classification and clinicopathological features of grade 3 endometrioid endometrial carcinoma

    Çukurova medical journal (Online)/Çukurova medical journal, 2025

    DOI 10.17826/cumj.1720831 Source: OpenAlex

  16. Predictors and treatment of ısolated recurrence in vulvar cancer confined to the vulva or perineum

    Journal of Cancer Research and Therapeutics, 2025

    DOI 10.4103/jcrt.jcrt_1698_24 PMID 41004296 Source: OpenAlex

  17. LIVER WEDGE RESECTION IN A CASE OF METASTATIC CHORIOCARCINOMA

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2025.102646 Source: OpenAlex

  18. TRANSDIAPHRAGMATIC VATS

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2025.102645 Source: OpenAlex

  19. Expression of HER2/neu, MUC1, Estrogen, and Progesterone Receptors in Epithelial Ovarian Cancer: Implications for Targeted Therapy: A Descriptive Research

    Journal of Clinical Obstetrics & Gynecology, 2025

    DOI 10.5336/jcog.2025-110315 Source: OpenAlex

  20. The Role of Colonoscopy in Advanced Stage Ovarian Cancer and Examination of the Characteristics of Patients with Mucosal Intestinal Metastases

    DergiPark (Istanbul University), 2025

    Source: OpenAlex

  21. 43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.103550 Source: OpenAlex

  22. Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial

    Gynecologic Oncology, 2024

    DOI 10.1016/j.ygyno.2024.07.096 Source: OpenAlex

  23. DOMENICA study (GINECO-EN105b/ENGOT-en13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1)

    Annual Meeting of Korean Society of Gynecologic Oncology, 2024

    DOI 10.3802/jgo.2024.35.s2.p1 Source: OpenAlex

  24. 736 Molecular classification and clinical significance in recurrent endometrial adenocarcinomas

    International Journal of Gynecological Cancer, 2024

    DOI 10.1136/ijgc-2024-esgo.375 Source: OpenAlex

  25. 746 Molecular classification in patient with endometrial cancer undergoing fertility preserving approach

    International Journal of Gynecological Cancer, 2024

    DOI 10.1136/ijgc-2024-esgo.376 Source: OpenAlex

  26. Tumoral clearance of the right portal hilar area: surprises beyond ‘no visual disease’

    International Journal of Gynecological Cancer, 2024

    DOI 10.1136/ijgc-2024-005298 PMID 38627033 Source: OpenAlex

  27. Comparison of energy modalities used in the operation and lymphocele symptoms in endometrium cancer patients developing lymphocele after lymphadenectomy

    DergiPark (Istanbul University), 2024

    Source: OpenAlex

  28. Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey

    Cancers, 2023

    DOI 10.3390/cancers15225428 PMID 38001688 7 citations (Europe PMC) Source: OpenAlex

  29. The Cukurova score in the prediction of primary cytoreduction in ovarian cancer

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-004736 PMID 37945055 3 citations (Europe PMC) Source: OpenAlex

  30. #1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.899 Source: OpenAlex

  31. Laparoscopic radical hysterectomy and total vaginectomy for vaginal malignant melanoma with cervical metastasis

    Journal of the Turkish-German Gynecological Association, 2023

    DOI 10.4274/jtgga.galenos.2022.2022-4-5 PMID 36919709 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  32. Comparison of the effectiveness of liposomal doxorubicin and gemcitabine in patients with platinum-sensitive recurrent ovarian cancer receiving third-line chemotherapy.

    PubMed, 2023

    DOI 10.26355/eurrev_202307_33132 PMID 37522673 1 citation (Europe PMC) Source: OpenAlex

  33. The effect of clinicopathological features on prognosis in malignant ovarian germ cell tumors

    Çukurova medical journal (Online)/Çukurova medical journal, 2023

    DOI 10.17826/cumj.1176706 Source: OpenAlex

  34. Epitelyal over kanserlerinde obezite ile asit ilişkisi ve sağkalıma etkisi

    Türk Jinekolojik Onkoloji Dergisi, 2023

    DOI 10.59215/trsgo.1271226 Source: OpenAlex

  35. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.17_suppl.lba5506 Source: OpenAlex

  36. Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.tps5630 Source: OpenAlex

  37. Right diaphragmatic peritonectomy in extensive involvement of the coronary area: no touch principle

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-004446 PMID 37463746 Source: OpenAlex

  38. Prognostic significance of omental disease and the role of omentectomy in non-endometrioid endometrial cancer

    Ginekologia Polska, 2023

    DOI 10.5603/gpl.92225 PMID 37599572 Source: OpenAlex

  39. #526 Prognostic Significance Of Prognostic Nutritional Index In High-Grade Serous Ovarian Cancer: A Comparative Analysis With Other Prognostic Factors

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.598 Source: OpenAlex

  40. #86 The cukurova score in the prediction of primary cytoreduction in ovarian cancer: a preliminary study

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.511 Source: OpenAlex

  41. #668 Evaluation of vulvar squamous cell and glandular cell cancers, retrospective multicenter study

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.828 Source: OpenAlex

  42. GC-MS based metabolite fingerprinting of serous ovarian carcinoma and benign ovarian tumor

    European Journal of Mass Spectrometry, 2022

    DOI 10.1177/14690667221098520 PMID 35503418 6 citations (Europe PMC) Source: OpenAlex

  43. Predictability of lymph node involvement in uterus-confined endometrioid endometrial cancer by tumour size, pattern and location measured with transvaginal ultrasonography: can we save time?

    Journal of Obstetrics and Gynaecology, 2022

    DOI 10.1080/01443615.2022.2106831 PMID 35934993 5 citations (Europe PMC) Source: OpenAlex

  44. A randomized Phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort (329)

    Gynecologic Oncology, 2022

    DOI 10.1016/s0090-8258(22)01551-7 Source: OpenAlex

  45. 2022-RA-1313-ESGO Clinical significance of Her2/Neu, Muc1, estrogen and progesterone receptor expression in malignant epithelial ovarian tumors

    International Journal of Gynecological Cancer, 2022

    DOI 10.1136/ijgc-2022-esgo.688 Source: OpenAlex

  46. Cardiophrenic and costophrenic lymph node resection via subxiphoid approach only

    Journal of the Turkish-German Gynecological Association, 2022

    DOI 10.4274/jtgga.galenos.2022.2021-9-2 PMID 35263836 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  47. 2022-RA-1566-ESGO Cytology and HPV testing in cervical cancer screening: factors determining persistence and clearance

    International Journal of Gynecological Cancer, 2022

    DOI 10.1136/ijgc-2022-esgo.832 Source: OpenAlex

  48. Live surgical anatomy of the right upper quadrant after cytoreductive surgery

    International Journal of Gynecological Cancer, 2022

    DOI 10.1136/ijgc-2022-003894 PMID 36261244 Source: OpenAlex

  49. 2022-RA-1581-ESGO Evaluation of the relationship between patient characteristics and obesity with survival in epithelial ovarian tumors

    International Journal of Gynecological Cancer, 2022

    DOI 10.1136/ijgc-2022-esgo.750 Source: OpenAlex

  50. 2022-RA-1603-ESGO Contribution of adding routine endoscopy and colonoscopy to preoperative screening of patients with suspected ovarian cancer on surgical and oncological outcomes

    International Journal of Gynecological Cancer, 2022

    DOI 10.1136/ijgc-2022-esgo.754 Source: OpenAlex